IBDEI2TD ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,47246,0)
 ;;=C81.02^^209^2346^374
 ;;^UTILITY(U,$J,358.3,47246,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47246,1,3,0)
 ;;=3^Nodular Lymphocyte Predominant Hodgkin Lymphoma,Intrathoracic Nodes
 ;;^UTILITY(U,$J,358.3,47246,1,4,0)
 ;;=4^C81.02
 ;;^UTILITY(U,$J,358.3,47246,2)
 ;;=^5001393
 ;;^UTILITY(U,$J,358.3,47247,0)
 ;;=C81.03^^209^2346^375
 ;;^UTILITY(U,$J,358.3,47247,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47247,1,3,0)
 ;;=3^Nodular Lymphocyte Predominant Hodgkin Lymphoma,Intra-Abdominal Nodes
 ;;^UTILITY(U,$J,358.3,47247,1,4,0)
 ;;=4^C81.03
 ;;^UTILITY(U,$J,358.3,47247,2)
 ;;=^5001394
 ;;^UTILITY(U,$J,358.3,47248,0)
 ;;=C81.04^^209^2346^376
 ;;^UTILITY(U,$J,358.3,47248,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47248,1,3,0)
 ;;=3^Nodular Lymphocyte Predominant Hodgkin Lymphoma,Axilla/Upper Limb Nodes
 ;;^UTILITY(U,$J,358.3,47248,1,4,0)
 ;;=4^C81.04
 ;;^UTILITY(U,$J,358.3,47248,2)
 ;;=^5001395
 ;;^UTILITY(U,$J,358.3,47249,0)
 ;;=C81.05^^209^2346^377
 ;;^UTILITY(U,$J,358.3,47249,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47249,1,3,0)
 ;;=3^Nodular Lymphocyte Predominant Hodgkin Lymphoma,Ing Region/Lower Limb Nodes
 ;;^UTILITY(U,$J,358.3,47249,1,4,0)
 ;;=4^C81.05
 ;;^UTILITY(U,$J,358.3,47249,2)
 ;;=^5001396
 ;;^UTILITY(U,$J,358.3,47250,0)
 ;;=C81.06^^209^2346^378
 ;;^UTILITY(U,$J,358.3,47250,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47250,1,3,0)
 ;;=3^Nodular Lymphocyte Predominant Hodgkin Lymphoma,Intrapelvic Lymph Nodes
 ;;^UTILITY(U,$J,358.3,47250,1,4,0)
 ;;=4^C81.06
 ;;^UTILITY(U,$J,358.3,47250,2)
 ;;=^5001397
 ;;^UTILITY(U,$J,358.3,47251,0)
 ;;=C81.07^^209^2346^379
 ;;^UTILITY(U,$J,358.3,47251,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47251,1,3,0)
 ;;=3^Nodular Lymphocyte Predominant Hodgkin Lymphoma,Spleen
 ;;^UTILITY(U,$J,358.3,47251,1,4,0)
 ;;=4^C81.07
 ;;^UTILITY(U,$J,358.3,47251,2)
 ;;=^5001398
 ;;^UTILITY(U,$J,358.3,47252,0)
 ;;=C81.08^^209^2346^380
 ;;^UTILITY(U,$J,358.3,47252,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47252,1,3,0)
 ;;=3^Nodular Lymphocyte Predominant Hodgkin Lymphoma,Mult Site Nodes
 ;;^UTILITY(U,$J,358.3,47252,1,4,0)
 ;;=4^C81.08
 ;;^UTILITY(U,$J,358.3,47252,2)
 ;;=^5001399
 ;;^UTILITY(U,$J,358.3,47253,0)
 ;;=C81.09^^209^2346^381
 ;;^UTILITY(U,$J,358.3,47253,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47253,1,3,0)
 ;;=3^Nodular Lymphocyte Predominant Hodgkin Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,47253,1,4,0)
 ;;=4^C81.09
 ;;^UTILITY(U,$J,358.3,47253,2)
 ;;=^5001400
 ;;^UTILITY(U,$J,358.3,47254,0)
 ;;=C81.10^^209^2346^382
 ;;^UTILITY(U,$J,358.3,47254,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47254,1,3,0)
 ;;=3^Nodular Sclerosis Classical Hodgkin Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,47254,1,4,0)
 ;;=4^C81.10
 ;;^UTILITY(U,$J,358.3,47254,2)
 ;;=^5001401
 ;;^UTILITY(U,$J,358.3,47255,0)
 ;;=C81.11^^209^2346^383
 ;;^UTILITY(U,$J,358.3,47255,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47255,1,3,0)
 ;;=3^Nodular Sclerosis Classical Hodgkin Lymphoma,Head/Face/Neck Nodes
 ;;^UTILITY(U,$J,358.3,47255,1,4,0)
 ;;=4^C81.11
 ;;^UTILITY(U,$J,358.3,47255,2)
 ;;=^5001402
 ;;^UTILITY(U,$J,358.3,47256,0)
 ;;=C81.12^^209^2346^384
 ;;^UTILITY(U,$J,358.3,47256,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47256,1,3,0)
 ;;=3^Nodular Sclerosis Classical Hodgkin Lymphoma,Intrathoracic Nodes
 ;;^UTILITY(U,$J,358.3,47256,1,4,0)
 ;;=4^C81.12
 ;;^UTILITY(U,$J,358.3,47256,2)
 ;;=^5001403
 ;;^UTILITY(U,$J,358.3,47257,0)
 ;;=C81.13^^209^2346^385
 ;;^UTILITY(U,$J,358.3,47257,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47257,1,3,0)
 ;;=3^Nodular Sclerosis Classical Hodgkin Lymphoma,Intra-Abdominal Nodes
